Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Zeal save search
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
Published: 2022-05-19 (Crawled : 12:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: 18.8%
H: 2.81%
C: -0.79%
pharma trial positive results phase 3
Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)
Published: 2022-02-15 (Crawled : 07:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: 2.54%
H: 2.06%
C: 1.0%
trial children insulin phase 3 ism enroll pharma
Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Published: 2022-01-20 (Crawled : 13:00) - biospace.com/
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -0.28%
H: 0.28%
C: -2.36%
trial phase 3 syndros enroll pharma
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Published: 2021-12-16 (Crawled : 09:00) - biospace.com/
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -2.37%
H: 0.0%
C: -0.11%
trial phase 3 syndros enroll
Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Published: 2021-08-19 (Crawled : 14:00) - biospace.com/
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: 2.13%
H: 0.63%
C: 0.63%
phase 3 trial syndros
Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes
Published: 2021-05-03 (Crawled : 18:00) - biospace.com/
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: 0.55%
H: 1.25%
C: -0.69%
diabetes treatment hypoglycemia phase 3 trial
Zealand Pharma announces data from the first phase 3-trial with dasiglucagon in Congenital Hyperinsulinism (CHI)
Published: 2020-12-15 (Crawled : 14:01) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -10.58%
H: 2.98%
C: 2.97%
insulin phase 3 trial pharma
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.